Key Market Indicators
Revenue from Czech antirheumatic medicine sales is predicted to hit $101 million by 2026. This is up 1% from 2021's total of $96 million. Since 1995, the Czech market has grown by an average of 5.6% each year. The country is currently ranked 8th in terms of revenue, behind Portugal, Germany, Spain and Canada.